Women with suspected ischemia and no obstructive coronary artery disease (INOCA) have a high prevalence of coronary microvascular dysfunction (CMD) 1 and an elevated major adverse cardiac event (MACE) rate, including nonfatal myocardial infarction (MI) 2 . Cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) imaging accurately visualizes and characterizes myocardial scar which predicts MACE 3 . The prevalence, incidence and scar pattern in women with INOCA is not well characterized. We evaluated LGE in women with suspected INOCA in the Women's Ischemia Syndrome Evaluation -Coronary Vascular Dysfunction (WISE-CVD) study. (Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00832702.) WISE-CVD participants were women with suspected INOCA, as previously described 4 . The study was approved by the site institutional review committees; all participants gave informed consent. Data are available from the corresponding author upon request. Of the 369 total women enrolled, 341/369 underwent baseline CMR with LGE; 1 was excluded due to inadequate quality. A subset of 145/340 underwent invasive coronary reactivity testing
(CRT) 5 . The Seattle Angina Questionnaire (SAQ) was completed at baseline and one year follow-up. Retrospective review included clinical diagnosis of MI, electrocardiogram and troponin levels. A subset of 200 participants underwent repeat CMR with LGE at one year follow-up; 179 were included with baseline CMR and follow-up within one year of study completion.
All scans were performed on a 1.5T scanner (Magnetom Avanto, Siemens Healthcare) and analyzed by the WISE CMR core lab 4 . A total 0.2 mmol/kg gadolinium-based contrast (Optimark, gadoversetamide) in divided doses was used, and LGE images were acquired using a 2D inversion-recovery turbo FLASH (slice thickness 8 mm, skip 2 mm, TE 3 ms, TR 0.7 s, flip angle 25 degrees). Scans were read blinded to clinical information; extent of LGE was quantified using the full-width at half-maximum method. LGE type was defined as "typical scar pattern" when subendocardial or transmural and localized to a coronary artery distribution, and "atypical scar pattern" when mid-myocardial or epicardial. LGE quantification was performed by a single experience operator using post-processing software (QMass, Medis), by delineating regions of LGE across all the multi-slice short axis acquisitions. Fisher's exact or two sample t-tests were used to compare groups. Linear regression with log transformation of the troponin variable was used to assess the relationship between troponin level and scar size.
LGE was present at baseline in 26 (8%) women, who were younger, had lower blood pressure, more likely to be prescribed calcium channel blockers and clopidogrel, and had lower SAQ treatment satisfaction, compared to women without LGE (Table) . Women with LGE also had lower left ventricular ejection fractions and higher end-diastolic and endsystolic volumes, but no difference in myocardial perfusion reserve index. There were also no differences in the invasive variables in the CRT subset.
Of the 26 participants with baseline LGE, 18 (69%) had a documented prior history of MI, with troponin available in 17/18 participants. Average peak troponin level was 25.5 ng/mL (median 4.3, min 0.1, max 250.0 ng/mL). There was no significant relationship between troponin level and scar size (p=0.18). In addition, 24/26 (92%) participants had electrocardiograms available for review, and 2/24 (1 with typical scar, 1 with atypical scar) demonstrated pathologic Q waves consistent with prior MI.
Most LGE cases (18/26) demonstrated a typical scar pattern, with vascular distributions in the LAD (4), LCX (8), RCA (4), LAD and LCX (1), LAD and RCA (1). Atypical scar cases (8/26, 31%) were patchy epicardial (6), subepicardial right ventricular (1), or midmyocardial septal pattern (1) . Compared to typical scar pattern, atypical scar pattern tended to be in younger (45±12 vs 53±9 years, p=0.068) participants with larger scar size (8.9±7.0 vs 5.1±3.6 grams, p=0.076).
Among the subset with 1-year CMR scans (n=179/340), new LGE was present in 1% (n=2/179), both were atypical scar pattern. Overall, 8% (n=14/179) had LGE in both baseline and one-year CMR, of which 71% (n=10/14) demonstrated a typical scar pattern; there was no one-year interval scar size change. Interval index events included 1 MI, 1 heart failure and 19 angina hospitalizations in 21 women (12%). Notably, both women with new
LGE had interval angina hospitalizations but no interval clinical diagnosis of MI. The one subject with a clinically diagnosed interval MI did not have interval LGE change.
In summary, among women with suspected INOCA, LGE prevalence was 8%, with an annual 1% new LGE incidence. One-third of our women with LGE did not have prior diagnosis of MI, suggesting that women with suspected INOCA not uncommonly have clinically under-diagnosed myocardial scar. Further phenotyping is needed to better understand women with typical vs atypical scar pattern, as conditions such as myocarditis or coronary vasospasm may have different clinical or prognostic impact. Longer follow-up is needed to determine whether CMR LGE predicts prognosis, changes clinical management and/or results in improved patient outcomes. Our results raise the importance of diagnosis and improved mechanistic understanding of INOCA, as well clinical trials to develop evidence-based treatment guidelines. Wei 
